Georgia's Online Cancer Information Center

Find A Doctor

Barry D. Luskey MD
Barry D. Luskey MD
Summit Cancer Care
www.summitcancercare.com

Barry D. Luskey MD

Specialty
Medical Oncology, Hematology / Board Certified
Trial Cancers
Adrenal Cancer, Bile Duct Cancer, Bladder Cancer, Bone Tumor, Brain & Spinal Cord Tumor, Brain Tumor, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Germ Cell Tumor, Gestational trophoblastic disease, Gynecologic Cancers, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Neuroendocrine Tumor, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Parathyroid Cancer, Penile Cancer, Plasma cell neoplasm, Primary Peritoneal Cancer, Prostate Cancer , Quality of Life, Retroperitoneal Tumors, Sarcoma, Skin Cancer (Non-Melanoma), Small Bowel Cancer, Solid Tumor, Stomach/ Gastric Cancer, Testicular Cancer, Thyroid Cancer, Ureter Cancer, Urethral Cancer, Uterine Cancer
Affiliations
St. Joseph's/Candler
Education

Medical School: University of Texas Southwestern Medical, Dallas, Texas

Internship: Brigham & Women's Hospital, Boston, Massachusetts

Residency: Brigham & Women's Hospital, Boston, Massachusetts

Fellowship: Brigham & Women's Hospital, Boston, Massachusetts, The Children's Hospital, Boston, Massachusetts

Active Clinical Trial Sites in Georgia



DeKalb Surgical Associates - Northside

980 Johnson Ferry Road, NE
Suite 430
Atlanta, GA 30342
404-508-4320 (p)
404-508-4112 (f)
www.dekalbsurgical.com

driving directions



Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler

225 Candler Drive
Savannah, GA 31405
912-819-5704 (p)
www.sjchs.org

driving directions

Clinical Trials
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Adrenal Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Bile Duct Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Bladder Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Bladder Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Bone Tumor

Immunotherapy with Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab with Cabozantinib for Patients with Advanced Kidney Cancer, The PDIGREE Study
Cancer Type: Bone Tumor

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Brain & Spinal Cord Tumor

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Brain Tumor

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Breast Cancer

Serum Tumor Marker Directed Disease Monitoring in Monitoring Patients with Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Cancer Type: Breast Cancer

Testing the Ability to Decrease Chemotherapy in Patients with HER2-Positive Breast Cancer Who Have No Remaining Cancer at Surgery after Limited Pre-operative Chemotherapy and HER2-Targeted Therapy
Cancer Type: Breast Cancer

T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Cancer Type: Breast Cancer

Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type: Breast Cancer

An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type: Cancer Control

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Cervical Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Cervical Cancer

Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Cancer Type: Colon/Rectal Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Colon/Rectal Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Colon/Rectal Cancer

Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type: Colon/Rectal Cancer

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Cancer Type: Colon/Rectal Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Esophogeal Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Esophogeal Cancer

Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Cancer Type: Esophogeal Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Gallbladder Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Gastrointestinal Stromal Tumor (GIST)

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Germ Cell Tumor

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Gestational trophoblastic disease

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Gynecologic Cancers

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Gynecologic Cancers

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Head and Neck Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Head and Neck Cancer

Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type: Hematopoietic Malignancies

Smoke Free Support Study 2.0
Cancer Type: Hematopoietic Malignancies

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Kidney Cancer

Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type: Kidney Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Liver Cancer / Hepatoblastoma

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Liver Cancer / Hepatoblastoma

Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type: Liver Cancer / Hepatoblastoma

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Lung Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Lung Cancer

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Lymphoma

Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type: Lymphoma

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Melanoma

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Mesothelioma

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Multiple Myeloma

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Multiple Myeloma

Testing the Addition of Daratumumab-Hyaluronidase to Enhance Therapeutic Effectiveness of Lenalidomide in Smoldering Multiple Myeloma, The DETER-SMM Trial
Cancer Type: Multiple Myeloma

Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type: Multiple Myeloma

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Neuroendocrine Tumor

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Non-Hodgkin Lymphoma

Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type: Non-Hodgkin Lymphoma

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Ovarian Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Ovarian Cancer

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Ovarian Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Pancreatic Cancer

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients with Pancreatic Cancer That Has Spread
Cancer Type: Pancreatic Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Parathyroid Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Penile Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Plasma cell neoplasm

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Plasma cell neoplasm

Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type: Plasma cell neoplasm

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Primary Peritoneal Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Prostate Cancer

Antiandrogen Therapy and Radiation Therapy with or without Docetaxel in Treating Patients with Prostate Cancer That Has Been Removed by Surgery
Cancer Type: Prostate Cancer

Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type: Prostate Cancer

CASPAR, A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Cancer Type: Prostate Cancer

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Retroperitoneal Tumors

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Sarcoma

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Skin Cancer (Non-Melanoma)

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Small Bowel Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Solid Tumor

Smoke Free Support Study 2.0
Cancer Type: Solid Tumor

Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
Cancer Type: Solid Tumor

Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type: Solid Tumor

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Cancer Type: Solid Tumor

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Stomach/ Gastric Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Stomach/ Gastric Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Testicular Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Thyroid Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Thyroid Cancer

Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Cancer Type: Unknown Primary

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Unknown Primary

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Unknown Primary

Antiandrogen Therapy and Radiation Therapy with or without Docetaxel in Treating Patients with Prostate Cancer That Has Been Removed by Surgery
Cancer Type: Unknown Primary

Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type: Unknown Primary

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Unknown Primary

Smoke Free Support Study 2.0
Cancer Type: Unknown Primary

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
Cancer Type: Unknown Primary

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients with Pancreatic Cancer That Has Spread
Cancer Type: Unknown Primary

Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type: Unknown Primary

CASPAR, A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Cancer Type: Unknown Primary

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Ureter Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Urethral Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Uterine Cancer

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib alone in Recurrent or Refractory Endometrial Cancer following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
Cancer Type: Uterine Cancer


Summit Cancer Care - Statesboro

16741 Highway 67 South
Suite B
Statesboro, GA 30458
912-871-8837 (p)
www.summitcancercare.com

driving directions



**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.